Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Arecor Therapeutics (LSE:AREC) in Focus Today: Insulin Partnerships and Cash Runway Drive the Biotech Debate

Arecor Therapeutics operates in formulation technology and development of insulin and other biologic medicines. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to convert expertise,Assetsor …

Ankur Sharma | 05 November 2026

Fusion Antibodies (LSE:FAB) in Focus Today: New Pharma Work Keeps Antibody Services in the Spotlight

Fusion Antibodies operates in pre-clinical antibody discovery, engineering andSupplyservices for therapeutic and diagnostic developers. This business model gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to …

Ankur Sharma | 05 November 2026

Genedrive (LSE:GDR) in Focus Today: Clinical Adoption Is the Next Test for Genedrive Diagnostics

Genedrive operates in molecular diagnostic tests and point-of-care genetic testing systems. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to convert expertise,Assetsor customer relationships into …

Ankur Sharma | 05 November 2026

Hikma Pharmaceuticals (LSE:HIK) Reshapes Its Growth Mix as FTSE 250 Investors Assess the Next Launch Cycle

• Investors are watching new launches, product mix and returns on research spending.

Ankur Sharma | 05 November 2026

Kromek Group (LSE:KMK) in Focus Today: New Imaging Order Gives Radiation Technology Shares a Fresh Catalyst

Kromek Group operates in radiation detection, advanced imaging and chemical, biological, radiological and nuclear detection technology. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to …

Ankur Sharma | 05 November 2026

Kooth (LSE:KOO) in Focus Today: Digital Mental Health Demand Faces a Contract Renewal Test

Kooth operates in digital mental-health services delivered through online platforms, including services for young people and adults. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability …

Ankur Sharma | 05 November 2026

Can Specialty Medicines Power the Next Chapter for GSK Plc (LSE:GSK)?

GSK Plc (LSE:GSK) shares rose 0.66% to 1,902.5p today, with attention on the pharmaceutical group's latest quarterly update and its continuing shift towards specialty medicines. The move follows a third-quarter report in which management reaffirmed its 2026 guidance.

Ankur Sharma | 05 November 2026

Haleon Plc (LSE:HLN): Can Everyday Health Brands Keep Compounding After a Reset in Growth Expectations?

Haleon Plc (LSE:HLN) shares rose 1.45% to 342.5p today, as the market continued to digest the consumer health group's third-quarter trading statement. The update included a lower organic growth outlook for 2026 alongside a further £500m share buyback.

Ankur Sharma | 05 November 2026

Convatec Group Plc (LSE:CTEC): Medical Devices, Buybacks and a Reset Around InnovaMatrix

Convatec Group Plc (LSE:CTEC) shares rose 0.71% to 255.8p today. The modest gain comes after first-half 2026 results that showed 5.0% organic growth excluding InnovaMatrix, a higherInterim Dividendand a new $200 million share buyback.

Ankur Sharma | 05 November 2026

AstraZeneca (LSE:AZN) Climbs: Oncology Momentum, Pipeline Readouts and a $3.30 Dividend in Focus

AstraZeneca Plc (LSE:AZN) shares rose 0.98% to 14,162.0p today, supported by continued attention on its latest quarterly update and a deep pipeline of late-stage medicines.

Ankur Sharma | 05 November 2026
Support

Hi! How can we help you today?

Loading…